Zobrazeno 1 - 10
of 66
pro vyhledávání: ''
Publikováno v:
International Journal of Molecular Medicine
Previous studies have reported that long non‑coding (lnc) RNA FGD5‑antisense 1 (FGD5‑AS1) promotes tumor proliferation, migration and invasion. Therefore, the present study aimed to elucidate the biological role and underlying molecular mechani
Publikováno v:
Oncology Reports
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used in the treatment of non‑small cell lung cancer (NSCLC). However, erlotinib resistance leads to high mortality in patients with NSCLC, while the ac
Publikováno v:
Oncology Letters
This study aimed to investigate the effect of bevacizumab on GLI1 and ING4 expression in colon cancer animal model. Colon cancer model in rats was induced by azoxymethane (AOM). Bevacizumab was used for the treatment of colon cancer rats. Tumor volum
Publikováno v:
International Journal of Molecular Medicine
Sphingosine-1-phosphate (S1P) serves an important role in various physiological and pathophysiological processes, including the regulation of cell apoptosis, proliferation and survival. Sphingosine kinase 1 (SPHK1) is a lipid kinase that phosphorylat
Publikováno v:
Molecular Medicine Reports
Oral squamous cell carcinoma (OSCC) is a cancer associated with high mortality (accounting for 3.1/100,000 deaths per year in Brazil in 2013) and a high frequency of amplification in the expression of the epidermal growth factor receptor (EGFR). Trea
Publikováno v:
Oncology Letters
Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel anticancer agent is used against multiple types of cancers, such as non-small cell lung cancer, head
Publikováno v:
Molecular Medicine Reports. 23
Cisplatin (DDP) resistance is a major obstacle in the chemotherapeutic efficacy of ovarian cancer. The present study aimed to explore the role of miR‑576‑3p in DDP sensitivity of ovarian cancer cells. Ovarian cancer cell lines SKOV3 and A2780 and
Autor:
Jianjie Zhu, Yuanyuan Zeng, Lin Sun, Zeyi Liu, Jian-An Huang, Xueting Wang, Yang Zhang, Ting Liu, Wenwen Du
Publikováno v:
Oncology Reports
Gefitinib is currently the preferred treatment for non‑small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)‑activating mutation. However, some patients gradually develop acquired resistance after receiving treatmen
Autor:
Zhangang Xiao, Jianhua Yin, Fukuan Du, Yuchen Zhang, Chengliang Huang, Yuanlin Wu, Parham Jabbarzadeh Kaboli, Jing Shen, Dandan Yuan, Chi Hin Cho, Xu Wu, Zhuo Zhang, Jing Li, Hanyu Zhang, Yueshui Zhao, Lan Lu, Mingxing Li
Publikováno v:
International Journal of Molecular Medicine
Cluster of differentiation 44 (CD44) as a transmembrane glycoprotein is found to be expressed in non-small cell lung cancer (NSCLC), is significantly associated with NSLC progression, metastasis and drug resistance. This study aimed to explore whethe
Publikováno v:
International Journal of Molecular Medicine
Resistance to the chemotherapeutic drug cisplatin has been documented in various types of cancer, while the increased expression of β‑catenin has been observed in cisplatin‑resistant ovarian cancer. However, the involvement of β‑catenin in ci